Business Context and Reporting Period
This Form 8-K was filed by JATT Acquisition Corp (JATT) on March 9, 2023, reporting events occurring on March 8, 2023. The filing concerns the proposed business combination between JATT and Zura Bio Ltd. JATT is a Cayman Islands-based emerging growth company with securities trading on the New York Stock Exchange under the symbols JATT, JATT WS, and JATT U.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins, as JATT is a special purpose acquisition company (SPAC) in the pre-combination phase. The document focuses on capital structure adjustments related to the pending merger:
- Forward Purchase Agreement Amendment: Purchasers (Athanor Master Fund, LP and Athanor International Master Fund, LP) agreed to purchase up to 1,500,000 Class A ordinary shares for an aggregate price of up to $15,000,000 if redemptions exceed certain thresholds.
- Share Issuance: Purchasers will receive an additional 2,500,000 Class A Shares upon the closing of the business combination.
- Post-Combination Ownership: Upon closing, Hana Immunotherapeutics LLC is expected to own 5,404,274 Class A Shares. Willow Gate LLC and Stone Peach Properties LLC are expected to own 2,702,623 and 2,701,543 Class A Shares, respectively.
Material Changes Versus Prior Period
The primary material change is the execution of Amendment No. 2 to the Forward Purchase Agreement. This amendment alters the source of shares for the forward purchase; previously, shares were to be purchased from public stockholders, but under the amendment, they will be purchased directly from the Company. Additionally, the amendment triggers the issuance of 2,500,000 additional shares to the Purchasers upon the closing of the Zura Bio combination.
Guidance, Outlook, Risks, and Contingencies
Outlook and Conditions: The completion of the business combination is contingent upon several factors, including shareholder approval, satisfaction of minimum cash requirements following redemptions, and receipt of governmental and regulatory approvals. The filing includes extensive forward-looking statements regarding the anticipated financial impacts and timing of the combination.
Risks and Contingencies: The filing highlights significant risks that could prevent the transaction from closing or alter its outcome, including:
- Failure to obtain shareholder approval or satisfy minimum cash requirements.
- Inability to meet the business combination deadline or secure an extension.
- Regulatory delays or adverse conditions in approvals.
- Volatility in the price of JATT or the combined company's securities.
- Operational disruptions and the inability to recognize anticipated benefits post-merger.
- Intellectual property enforceability and cybersecurity risks.
- Broader economic factors, including the impact of the global COVID-19 pandemic.
Important Facts for Investor Verification
- Verify the final redemption rate to determine if the $15,000,000 forward purchase threshold is triggered.
- Confirm the total post-combination share count and dilution impact resulting from the 2,500,000 additional shares issued to Purchasers.
- Review the Form S-4 and proxy statement for detailed terms of the lock-up restrictions (noting that Willow Gate and Stone Peach shares are exempt).
- Monitor regulatory approval status and the satisfaction of the minimum cash requirement condition.
- Assess the financial health and pipeline status of Zura Bio Ltd, as the filing relies heavily on the success of the target company.